Trevi Therapeutics Analyst Ratings
Trevi Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/22/2022 | 201.51% | SVB Leerink | → $6 | Initiates Coverage On | → Outperform |
| 11/11/2022 | 302.01% | Needham | $10 → $8 | Maintains | Buy |
| 06/30/2022 | 402.51% | Needham | $8 → $10 | Maintains | Buy |
| 05/25/2022 | 402.51% | Oppenheimer | → $10 | Initiates Coverage On | → Outperform |
| 03/29/2022 | 402.51% | Aegis Capital | → $10 | Initiates Coverage On | → Buy |
| 11/11/2021 | 302.01% | Needham | $10 → $8 | Maintains | Buy |
| 08/13/2021 | 402.51% | Needham | $12 → $10 | Maintains | Buy |
| 08/14/2020 | 352.26% | SVB Leerink | $8 → $9 | Maintains | Outperform |
| 07/13/2020 | 503.02% | Needham | $18 → $12 | Maintains | Buy |
| 06/03/2019 | 804.52% | Needham | → $18 | Initiates Coverage On | → Buy |
| 06/03/2019 | 653.77% | BMO Capital | → $15 | Initiates Coverage On | → Outperform |
| 06/03/2019 | 905.03% | Stifel | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 11/22/2022 | 201.51% | SVB Leerink | → $6 | 開始承保 | →跑贏大盤 |
| 11/11/2022 | 302.01% | 李約瑟 | $10 → $8 | 維護 | 買 |
| 06/30/2022 | 402.51% | 李約瑟 | $8 → $10 | 維護 | 買 |
| 05/25/2022 | 402.51% | 奧本海默 | → $10 | 開始承保 | →跑贏大盤 |
| 03/29/2022 | 402.51% | 宙斯盾資本 | → $10 | 開始承保 | →購買 |
| 11/11/2021 | 302.01% | 李約瑟 | $10 → $8 | 維護 | 買 |
| 08/13/2021 | 402.51% | 李約瑟 | $12 → $10 | 維護 | 買 |
| 08/14/2020 | 352.26% | SVB Leerink | $8 → $9 | 維護 | 跑贏大盤 |
| 07/13/2020 | 503.02% | 李約瑟 | $18 → $12 | 維護 | 買 |
| 06/03/2019 | 804.52% | 李約瑟 | → $18 | 開始承保 | →購買 |
| 06/03/2019 | 653.77% | 蒙特利爾銀行資本 | → $15 | 開始承保 | →跑贏大盤 |
| 06/03/2019 | 905.03% | Stifel | → $20 | 開始承保 | →購買 |
What is the target price for Trevi Therapeutics (TRVI)?
特雷維治療公司(TRVI)的目標價格是多少？
The latest price target for Trevi Therapeutics (NASDAQ: TRVI) was reported by SVB Leerink on November 22, 2022. The analyst firm set a price target for $6.00 expecting TRVI to rise to within 12 months (a possible 201.51% upside). 5 analyst firms have reported ratings in the last year.
特雷維治療公司(納斯達克代碼：TRVI)的最新目標價於2022年11月22日由SVB Leerink報道。這家分析公司將目標價定為6美元，預計TRVI將在12個月內升至(可能上漲201.51%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Trevi Therapeutics (TRVI)?
特雷維治療公司(TRVI)的最新分析師評級是多少？
The latest analyst rating for Trevi Therapeutics (NASDAQ: TRVI) was provided by SVB Leerink, and Trevi Therapeutics initiated their outperform rating.
特雷維治療公司(納斯達克代碼：TRVI)的最新分析師評級由SVB Leerink提供，特雷維治療公司啟動了其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Trevi Therapeutics (TRVI)?
特雷維治療公司(TRVI)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Trevi Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Trevi Therapeutics was filed on November 22, 2022 so you should expect the next rating to be made available sometime around November 22, 2023.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閲公共財務報表，與Trevi Treeutics的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Trevi治療公司的上一次評級是在2022年11月22日提交的，所以你應該預計下一次評級將在2023年11月22日左右提供。
Is the Analyst Rating Trevi Therapeutics (TRVI) correct?
分析師對Trevi Treeutics(TRVI)的評級正確嗎？
While ratings are subjective and will change, the latest Trevi Therapeutics (TRVI) rating was a initiated with a price target of $0.00 to $6.00. The current price Trevi Therapeutics (TRVI) is trading at is $1.99, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Trevi治療(TRVI)評級是以0.00美元至6.00美元的目標價啟動的。特雷維治療公司(TRVI)目前的交易價格為1.99美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。